M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.
News
Study supports lower starting dose of lenvatinib for endometrial cancer
A 14-mg dose was safer and just as effective as a 20-mg dose in a retrospective study.
News
Cytoreduction in advanced ovarian cancer: ‘Keep the status quo’
Debulking surgery should be considered whenever feasible, according to researchers.
News
Melatonin not recommended for early-stage NSCLC
There was a hint of benefit with melatonin among patients with stage III/IV NSCLC.
News
Delaying surgery didn’t impact survival in early-stage cervical cancer
The results are “reassuring” in light of the pandemic, according to an investigator.
News
Expert recommendations for targeted therapies in advanced NSCLC
The recommendations update guidance from 2017.
News
Ovarian cancer prevention: How patients decide on surgery
Twenty-four women reveal how they made a difficult decision.
News
Age should not be a barrier to aggressive esophageal cancer treatment
Comorbidities, fitness are what matters.
News
RPLND deemed ‘attractive’ option for early metastatic seminoma
The 2-year recurrence-free survival rate was 84% in a phase 2 trial.
News
CCR score can guide treatment decisions after radiation in prostate cancer
The score can identify patients with a low risk of metastasis who could potentially skip androgen deprivation therapy.
News
Cemiplimab approved for locally advanced, metastatic basal cell carcinoma
The approval is based on phase 2 trial results.
News
TBI beats chemoconditioning for ALL transplants in children
Total body irradiation plus etoposide remains the conditioning regimen of choice.